Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Should assessment of penetrative sexual activity be used as the treatment arbiter in the management of Peyronie's disease?

International Journal of Impotence Research volume 23, pages 70–75 (2011)Cite this article

Subjects

Abstract

Peyronie's disease is an inflammatory disorder, which causes thickening of the tunica albuginea of the penis. Peyronie’s disease has a variable natural history and the assessment and management of the disease has yet to be standardised. The case notes of 97 patients with a diagnosis of Peyronie's disease were retrospectively reviewed at a single tertiary referral centre. Patients who were able to achieve sexual penetrative activity to the satisfaction of both partners were managed conservatively. Patients who were unable to achieve penetrative sexual activity were given intra-cavernosal prostaglandin, with those achieving a satisfactory erection being offered appropriate surgical intervention. The mean age at presentation was 50 years (range 18–82). A total of 59 (61%) men were able to have penetrative sex at the time of presentation. Following initial conservative management, only five (8%) of this group had disease progression, which stopped them from being able to penetrate. In all 38 (39%) men who were not able to penetrate at presentation were offered surgical intervention. In all 24 (63%) of these men chose to have surgical intervention. Tunical plication resulted in the ability to penetrate in 77% of men choosing this option whereas only 46% of men undergoing autologous saphenous vein grafting were able to have penetrative sex. Assessment of penetrative sexual function is an essential component of the management of patients with Peyronie's disease. This enables appropriate counselling with respect to possible conservative management or the most appropriate surgical intervention. The majority of patients with Peyronie's disease can achieve sexual penetrative activity, many without surgical intervention.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U . The prevalence of Peyronie's disease: results of a large survey. BJU Int 2001; 88: 727–730.

    Article  CAS  Google Scholar 

  2. El-Sakka AI . Prevalence of Peyronie's disease among patients with erectile dysfunction. Eur Urol 2006; 49: 564–569.

    Article  Google Scholar 

  3. El-Sakka AI, Tayeb KA . Peyronie's disease in diabetic patients being screened for erectile dysfunction. J Urol 2005; 174: 1026–1030.

    Article  Google Scholar 

  4. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004; 171 (Part 1): 2350–2353.

    Article  Google Scholar 

  5. Hauck EW, Diemer T, Schmelz HU, Weidner W . A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006; 49: 987–997.

    Article  CAS  Google Scholar 

  6. Mulhall JP, Schiff J, Guhring P . An analysis of the natural history of Peyronie's disease. J Urol 2006; 175: 2115–2118.

    Article  Google Scholar 

  7. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S . A retrospective review of 307 men with Peyronie's disease. J Urol 2002; 168: 1075–1079.

    Article  Google Scholar 

  8. Levine LA, Greenfield JM . Establishing a standardized evaluation of the man with Peyronie's disease. Int J Impot Res 2003; 15 (Suppl 5): S103–S112.

    Article  Google Scholar 

  9. Gelbard MK, Dorey F, James K . The natural history of Peyronie's disease. J Urol 1990; 144: 1376–1379.

    Article  CAS  Google Scholar 

  10. Weidner W, Hauck EW, Schnitker J . Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005; 47: 530–535, discussion 535–536.

    Article  CAS  Google Scholar 

  11. Mynderse LA, Monga M . Oral therapy for Peyronie's disease. Int J Impot Res 2002; 14: 340–344.

    Article  CAS  Google Scholar 

  12. Safarinejad MR . Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004; 16: 238–243.

    Article  CAS  Google Scholar 

  13. Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA . Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999; 162: 2003–2005.

    Article  CAS  Google Scholar 

  14. Meacham RB . Nonsurgical management of Peyronie's disease—are we making any progress? J Urol 2006; 176: 12–13.

    Article  Google Scholar 

  15. Hellstrom WJG, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006; 176: 394–398.

    Article  CAS  Google Scholar 

  16. Gholami SS, Lue TF . Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol 2002; 167: 2066–2069.

    Article  Google Scholar 

  17. Thiounn N, Missirliu A, Zerbib M, Larrouy M, Dje K, Flam T et al. Corporeal plication for surgical correction of penile curvature. Experience with 60 patients. Eur Urol 1998; 33: 401–404.

    Article  CAS  Google Scholar 

  18. Geertsen UA, Brok KE, Andersen B, Nielsen HV . Peyronie curvature treated by plication of the penile fasciae. Br J Urol 1996; 77: 733–735.

    Article  CAS  Google Scholar 

  19. Kadioglu A, Sanli O, Akman T, Cakan M, Erol B, Mamadov F . Surgical treatment of Peyronie's disease: a single center experience with 145 patients. Eur Urol 2008; 53: 432–439.

    Article  Google Scholar 

  20. Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan M, Celtik M . Surgical treatment of Peyronie's disease: a critical analysis. Eur Urol 2006; 50: 235–248.

    Article  Google Scholar 

  21. Weidner W, Schroeder-Printzen I, Weiske W, Vosshenrich R . Sexual dysfunction in Peyronie's disease: an analysis of 222 patients without previous local plaque therapy. JUrol 1997; 157: 325–328.

    CAS  Google Scholar 

  22. Levine LA, Lenting EL . A surgical algorithm for the treatment of Peyronie's disease. J Urol 1997; 158: 2149–2152.

    Article  CAS  Google Scholar 

  23. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM . Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326.

    Article  CAS  Google Scholar 

  24. Martínez-Jabaloyas JM, Gil-Salom M, Villamón-Fort R, Pastor-Hernández F, Martínez-García R, García-Sisamón F . Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol 2001; 40: 641–646, discussion 647.

    Article  Google Scholar 

  25. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47–52.

    CAS  PubMed  Google Scholar 

  26. Gonzalez-Cadavid NF, Rajfer J . Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol 2010; 7: 215–221.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

No funding was accepted for this research. Ethical approval was not applicable as the article is a retrospective review of care provided and subsequent outcomes.

Author information

Authors and Affiliations

  1. Department of Urology, Manchester Royal Infirmary, Manchester, UK

    I Dukic, N Thakare, I Pearce & S R Payne

Authors
  1. I Dukic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Thakare
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I Pearce
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S R Payne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I Dukic.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dukic, I., Thakare, N., Pearce, I. et al. Should assessment of penetrative sexual activity be used as the treatment arbiter in the management of Peyronie's disease?. Int J Impot Res 23, 70–75 (2011). https://doi.org/10.1038/ijir.2011.6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2011.6

Keywords

This article is cited by

Search

Advanced search

Quick links